8-K 1 v142403_8k.htm Unassociated Document

 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
_________________
 
 
 
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 9, 2009 (March 5, 2009)
 
(Exact Name of Registrant as Specified in Charter)
 
(State or Other Jurisdiction of Incorporation)
000-33271
(Commission File Number)
98-022951
(IRS Employer Identification No.)

5800 Metropolitan Blvd. E., Suite 328
Montreal, Quebec
(Address of Principal Executive Offices )
H1S 1A7
 (Zip Code)
 
Registrant’s telephone number, including area code:   (514) 333-4545
 
 
 
o  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 


Effective March 5, 2009, Frederic Blondeleau resigned as Vice President – Sales and Marketing of Global Biotech Corp.  At this time, no replacement has been appointed to fill Mr. Blondeleau’s position.

 
2
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
GLOBAL BIOTECH CORP.
   
   
Date: March 9, 2009
   /s/ Louis Greco
 
Louis Greco
 
President and Chief Executive Officer


 
3